SAN DIEGO, March 7, 2005 /PRNewswire-FirstCall via COMTEX/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced the appointments of Brian Lundstromto Senior Vice President, Business Development, Daniel P. van Kammen, M.D.,Ph.D., to Vice President, Clinical Development, and Douglas W. Bonhaus, Ph.D.,to Vice President, Biosciences.
"These appointments serve to further strengthen our organization in keyareas that will drive success for ACADIA as we continue to mature our clinicalpipeline and position selected programs for strategic commercial alliances,"said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. "With theseadditions, we not only have enhanced our partnering capabilities, but alsohave added additional cutting edge expertise in both our clinical andpre-clinical organizations."
Brian Lundstrom, Senior Vice President, Business Development
Mr. Lundstrom has joined ACADIA as Senior Vice President, BusinessDevelopment. Mr. Lundstrom was previously Vice President, BusinessDevelopment at Genzyme Corporation where he led the integration andoutlicensing of assets from his previous employer, SangStat MedicalCorporation, until the sale of that company to Genzyme. Mr. Lundstrom hasbroad industry experience and a proven track record in business development,having executed over 40 deals on discovery technologies, clinical-stageproduct candidates and marketed products in his career. Mr. Lundstrom alsohas held senior business, clinical, and product development positions atOxford LycoSciences (now UCB Bioproducts) and Novo Nordisk. Mr. Lundstrom hasa Master of Science in Chemical Engineering with a biotechnologyspecialization from the Danish Technology University and an MBA equivalentdegree in International Business and Finance from Copenhagen Business Schooland Seattle University.
Daniel P. van Kammen, M.D., Ph.D., Vice President, Clinical Development
Dr. van Kammen has joined ACADIA as Vice President, Clinical Development.Dr. van Kammen joined ACADIA from Aventis, where he served as Head of CNS,Clinical Discovery and Human Pharmacology and was co-responsible for Aventis'schizophrenia strategy. Prior to Aventis, he was Senior Director, GlobalDevelopment, at J&J Pharmaceutical Research and Development. Dr. van Kammenhas extensive experience in CNS strategy and program development and hasdirected a wide range of CNS clinical programs, including those in the fieldsof schizophrenia and sleep disorders. Dr. van Kammen received a Ph.D. inPharmacology from the University of Utrecht in the Netherlands. He holds anM.D. from the University of Utrecht Medical School and completed his residencyin psychiatry at Johns Hopkins Hospital.
Douglas W. Bonhaus, Ph.D., Vice President, Biosciences
Dr. Bonhaus has joined ACADIA as Vice President, Biosciences. Dr. Bonhausjoins ACADIA from Roche, where he was Department Head. Dr. Bonhaus has over13 years of experience in the biopharmaceutical industry, which includesestablishing discipline-based research groups and leading drug discovery anddevelopment programs for CNS disorders, particularly in the areas ofneuropsychiatric disorders, neuropathic pain, and migraine. He also servedfor four years as Research Assistant Professor in the Department of Medicine,Neurology Division, at Duke University. Dr. Bonhaus received a Ph.D. degreein Pharmacology and Toxicology from the University of Arizona and a Bachelorof Science degree in Physiology from Michigan State University.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of novel treatmentsfor central nervous system disorders. ACADIA currently has four drug programsin clinical development as well as a portfolio of preclinical and discoveryassets directed at large unmet medical needs, including schizophrenia,Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietarydrug discovery platform, ACADIA has discovered all of the drug candidates inits product pipeline. ACADIA's corporate headquarters and biology researchfacilities are located in San Diego, California and its chemistry researchfacilities are located near Copenhagen, Denmark.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but are notlimited to statements related to the progress and timing of our drug discoveryand drug development programs and our clinical trials, the potential for newcollaborations, and our future results. These statements are only predictionsbased on current information and expectations and involve a number of risksand uncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, including therisks and uncertainties inherent in drug development and commercialization andforming partnerships and alliances. For a discussion of these and otherfactors, please refer to ACADIA's registration statement on Form S-1 as wellas other subsequent filings with the Securities and Exchange Commission. Youare cautioned not to place undue reliance on these forward-looking statements,which speak only as of the date hereof. This caution is made under the safeharbor provisions of the Private Securities Litigation Reform Act of 1995.All forward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise or updatethis press release to reflect events or circumstances after the date hereof.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871